Live Analyst Rating Changes 28468 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Debanjana Chatterjee
JONE

Debanjana Chatterjee

JonesTrading
Wall Street Analyst
★★★☆☆
#1609
on 13Foresight · ranked by our own returns
55%
Success Rate
+1.8%
Average Return
27 of 49 calls profitable · +0.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 55% of Debanjana Chatterjee's ratings turned a profit when each position was held for 1 year — averaging +1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

145 Buy 10 Hold 0 Sell
Debanjana's Stock Coverage 18 ratings · 2026-08-29
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SYRE
Spyre Therapeutics
 Aug 26, 2026 BUY Strong Buy
+1.6% avg upside
23 analysts
$121.00
29.26% Upside
 · ·
SGMT
Sagimet Biosciences, Inc. Class A
 Aug 25, 2026 BUY Strong Buy
+169.1% avg upside
15 analysts
$31.00
188.43% Upside
 · ·
EVAX
Evaxion Biotech
 Aug 21, 2026 BUY Strong Buy
+307.6% avg upside
6 analysts
$10.00
217.37% Upside
 -4.8% ·
EYPT
EyePoint Pharmaceuticals
 Aug 18, 2026 BUY Strong Buy
+423.2% avg upside
21 analysts
$20.00
331.93% Upside
 -7.7% ·
NTLA
Intellia Therapeutics
 Aug 14, 2026 BUY Buy
+198.5% avg upside
37 analysts
$29.00
121.15% Upside
 +7.8% ·
TRVI
Trevi Therapeutics
 Aug 13, 2026 BUY Strong Buy
+41.2% avg upside
18 analysts
$28.00
55.85% Upside
 -1.1% ·
ATHE
Alterity Therapeutics
 Aug 12, 2026 BUY Strong Buy
+117.5% avg upside
7 analysts
$16.00
250.91% Upside
 -9.0% ·
ABSI
AbSci
 Aug 12, 2026 BUY Strong Buy
+35.7% avg upside
18 analysts
$13.00
37.92% Upside
 +0.5% ·
SION
Sionna Therapeutics, Inc.
 Aug 10, 2026 HOLD Hold
+269.0% avg upside
12 analysts
$63.00
939.53% Upside
 +17.6% ·
TVRD
Tvardi Therapeutics
 Aug 10, 2026 BUY Buy
+872.2% avg upside
23 analysts
$12.00
566.60% Upside
 +2.3% ·
ABCL
AbCellera Biologics
 Aug 10, 2026 BUY Strong Buy
+38.8% avg upside
15 analysts
$25.00
101.59% Upside
 +28.6% ·
CTNM
Contineum Therapeutics, Inc. Class A
 Jul 31, 2026 BUY Strong Buy
+28.2% avg upside
9 analysts
$26.00
50.82% Upside
 +10.4% ·
IRD
Opus Genetics
 Jul 30, 2026 BUY Strong Buy
+177.2% avg upside
25 analysts
$10.00
159.75% Upside
 +5.5% ·
HYFT
MindWalk Holdings
 Jul 23, 2026 BUY Strong Buy
+207.6% avg upside
3 analysts
$5.00
252.12% Upside
 +20.3% ·
TBPH
Theravance Biopharma
 Jun 29, 2026 HOLD Buy
+8.2% avg upside
18 analysts
$17.00
0.28% Downside
 -0.2% ·
PHVS
Pharvaris
 Jun 11, 2026 BUY Strong Buy
+29.2% avg upside
15 analysts
$52.00
40.45% Upside
 +14.9% ·
ARMP
Armata Pharmaceuticals
 May 27, 2026 BUY Strong Buy
+159.1% avg upside
4 analysts
$20.00
268.30% Upside
 -31.9% ·
CYVNY
Ceryvyn Therapeutics Limited
 May 22, 2026 HOLD Hold
+32227.6% avg upside
7 analysts
 — -34.3% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Debanjana Chatterjee — Frequently Asked Questions
How accurate are Debanjana Chatterjee's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Debanjana's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, or +0.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Debanjana ranked on 13Foresight?
Debanjana Chatterjee is currently ranked #1609 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Debanjana cover?
Debanjana most recently has ratings on SYRE, SGMT, EVAX, EYPT, NTLA, TRVI, ATHE, ABSI, SION, TVRD, ABCL, CTNM and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.